ADVM stock forecast
Our latest prediction for Adverum Biotechnologies, Inc.'s stock price was made on the Dec. 23, 2019 when the stock price was at 11.06$.
In the short term (2weeks), ADVM's stock price should underperform the market by -4.91%. During that period the price should oscillate between -10.31% and +11.23%.
In the medium term (3months), ADVM's stock price should underperform the market by -9.67%. During that period the price should oscillate between -39.36% and +30.80%.Get email alerts
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.95$ per share.
The book value per share is 3.72$
Three months stock forecastDec. 23, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|